

## TECHNICAL SPECIFICATIONS


Drug / Excipient	
Drug	Sirolimus
Drug Dose	0.7 µg/mm <sup>2</sup>
Drug Carrier	Customized biodegradable polymer matrix
Stent	
Stent Material	L605 Cobalt Chromium Alloy
Strut Thickness	73 µm
Strut Width	80 µm (hinge) - 120 µm (strut)

Delivery System	
Delivery System	RX/Monorail
Nominal Pressure	8 Bar
Rated Burst Pressure	14 Bar*
Guidewire Compatibility (max)	0.014"
Guiding Catheter Compatibility	5F
Crossing Profile**	0.038"
Tip Entry Profile	0.016"

\* Do not exceed RBP  
 \*\* Reference diameter of 3.00 mm

## ORDERING INFORMATION

Stent Dia (mm)	Stent Length (mm)											
	08	12	16	20	24	28	32	36	40	44	48	52
2.25	EAN22508	EAN22512	EAN22516	EAN22520	EAN22524	EAN22528	EAN22532	EAN22536	EAN22540	-	-	-
2.50	EAN25008	EAN25012	EAN25016	EAN25020	EAN25024	EAN25028	EAN25032	EAN25036	EAN25040	EAN25044	EAN25048	EAN25052
2.75	EAN27508	EAN27512	EAN27516	EAN27520	EAN27524	EAN27528	EAN27532	EAN27536	EAN27540	-	-	-
3.00	EAN30008	EAN30012	EAN30016	EAN30020	EAN30024	EAN30028	EAN30032	EAN30036	EAN30040	EAN30044	EAN30048	EAN30052
3.50	EAN35008	EAN35012	EAN35016	EAN35020	EAN35024	EAN35028	EAN35032	EAN35036	EAN35040	EAN35044	EAN35048	EAN35052
4.00	EAN40008	EAN40012	EAN40016	EAN40020	EAN40024	EAN40028	EAN40032	EAN40036	EAN40040	EAN40044	EAN40048	EAN40052
4.50	EAN45008	EAN45012	EAN45016	EAN45020	-	-	-	-	-	-	-	-
5.00	EAN50008	EAN50012	EAN50016	EAN50020	-	-	-	-	-	-	-	-



\*The above diagram is just an illustration of the product.  
 Disclaimer: The law restricts these devices to sale by or on the order of a physician. Indications, contradictions, warnings can be found in the product labelling / IFU supplied with each device. For restricted use only in countries where product is registered with applicable health authorities.



# Concept Medical

# ABLUMINUS DES+

## SIROLIMUS ELUTING CORONARY STENT SYSTEM

DES + DCB\* = DES+

\*drug coating on exposed parts of balloon

Approved Indication for DM and AMI

# Concept Medical

f t @ in /conceptmedicals

✉ info@conceptmedical.com

🌐 www.conceptmedical.com

Scan for more details




CB.ST.AN.BRO.ver.1.1.21-05


## DIABETES MELLITUS

- Patients with DM are more affected by coronary artery disease and when treated by PCI with stent implantation they remain at higher risk of in-stent restenosis and adverse cardiovascular events.<sup>[1-3]</sup>
- The etiology of this failure is likely to be multifactorial such as diffuse disease progression, small vessel and endothelial dysfunction.<sup>[4-9]</sup>
- The presence of DM (particularly insulin-treated DM) has been a consistent, independent predictor of in-stent restenosis.<sup>[10]</sup>

## STENT COMPARISON\*




\* GG Stefanini, M Taniwaki, S Windecker, Coronary stents: novel development, Heart doi:10.1136/heartjnl-2012-303522; I Meredith, Scientific symposium, CT 2013; M Rothman, presentation TCT 2014



## CELL DESIGN



**Labelled Diameter**  
2.25 mm  
2.50 mm  
**Side Branch Access**  
4.00 mm



**Labelled Diameter**  
2.75 mm  
3.00 mm  
3.50 mm  
**Side Branch Access**  
5.30 mm

**8 Cell Design**



**Labelled Diameter**  
4.00 mm  
4.50 mm  
5.00 mm  
**Side Branch Access**  
6.70 mm

**10 Cell Design**

## ABLUMINAL COATING

Facilitates mono directional drug release and less systemic exposure of drug leading to faster re-endothelialisation



## FUSION COATING

Coating on the stent and exposed parts of the balloon facilitate homogeneous drug delivery which addresses diffused proliferative disease and focal restenosis



## EDGE COATING

Additional 0.5 mm coating beyond the proximal and distal edge of the stent addresses the edge restenosis



## BIODEGRADABLE FILM

The formation of hypothetical circular film with biodegradable polymer due to elasticity of polymer facilitate maximum surface area for drug delivery in blood wet conditions



**DES + DCB\* = DES+**

Designed to treat diabetic patients

\*drug coating on exposed parts of balloon



### References:

1. Kereiakes DJ et al. J Am Coll Cardiol 2010; 56: 2084-9. | 2. Cutlip DE et. al. Circulation 2004; 110: 1226-30. | 3. Lee TT et al Am J Cardiol 2006; 98:718-21. | 4. Morgan KP et al. Heart 2004; 90: 732-8. | 5. Hadi H a R et al. Vasc Health Risk Manag 2007; 3:853-76. | 6. Schalkwijk CG et. Al Clin Sci 2005; 109: 143-59. | 7. Dangas GD et al. J. Am. Coll. Cardiol. 2010; 56:1897-907. | 8. Lightell DJ et al. Ochsner J 2013; 13:56-60. | 9. Denardo SJ et al. JAMA 2012; 307:2148-50. | 10. Popma, J.J. et al. Circulation 110, 3773-3780 (2004).